Company Dossier · Health Care
DaVita
- S&P 500
- Russell 1000
What DaVita is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $14.0 billion, up 6.5% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $1.61 billion, up 25% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.58 billion, up 1.8% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $1.31 billion.SEC EDGAR filings (10-K)
- Long-term debt issued in the fiscal year to December 31, 2025: $5.61 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (August 4, 2026): sentiment 0.20 on a −1 to +1 scale (mixed), confidence 0.70 of 1.Palanor Discourse
- Guidance in the last 90 days: 0 outlook figures raised, 0 lowered, 2 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 11, 2026): 5 risk factors added, 6 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $36.5 million on the open market.SEC Form 4
- 633 institutional managers reported a position at June 30, 2026 (+49 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 20 (19 a year earlier).U.S. Department of Labor (OFLC)
Risk events (12 months): 1 — latest OSHA inspection, Nov 21, 2025 →
Company Posture
How Company Posture is measured →What DaVita is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Steady · Mixed
Expanding ↔ Retrenching
Steady
- Capital spending53rd pct
- Debt raised56th pct
- Buybacks vs capex66th pct
- Hiring filings34th pct
- Deals and private raises49th pct
- Patent publications60th pct
Confident ↔ Hedging
Mixed
- Call sentiment26th pct
- Call confidence47th pct
- Guidance changes69th pct
- Risk factors added8th pct
- Insider open-market trades44th pct
- − Risk factors added
- − Call sentiment
- + Guidance changes
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver82nd pct
- Stress filings48th pct
Credit
How these are built →DaVita's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$10.8B
- Due within a year $0.1B
- Longer term $10.7B
- Default point $5.4B (short + ½ long)
Finance leases included · Jun 30, 2026 filing
Bonds priced, last 12 months
None
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
DaVita: earnings call confidence
Palanor Discourse score per call, 0 to 1
Hiring and ownership
In the news
Headlines that name DaVita, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- PositiveDaVita: After A 25% Drop, The Buyback Machine Is Cheap Again (NYSE:DVA)
seekingalpha.com · via Marketaux · Oct 9, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 21, 2026LobbyingLobbying report (COLETTE DESMARAIS)third_quarter 2026
- Oct 21, 2026LobbyingLobbying report (FEDERAL STREET STRATEGIES, LLC)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (POWERS PYLES SUTTER & VERVILLE, P.C.)third_quarter 2026 · $0.0 million
- Oct 20, 2026LobbyingLobbying report (CAPITOL HILL CONSULTING GROUP)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (RED+BLUE STRATEGIES)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (DAVITA INC.)third_quarter 2026 · $1.1 million
- Oct 19, 2026LobbyingLobbying report (CONTINENTAL STRATEGY, LLC)third_quarter 2026 · $0.1 million
- Oct 16, 2026LobbyingLobbying report (S-3 GROUP)third_quarter 2026 · $0.1 million
- Jun 8, 20268-KMaterial agreement signedItem 1.01
- Jun 8, 20268-KShareholder vote resultsItem 5.07
- Mar 13, 2026Trademark
- Mar 13, 2026Trademark
- Feb 11, 202610-KAnnual report (10-K)5 risk factors added, 6 removed
- Nov 25, 20258-KMaterial agreement signedItem 1.01
- Nov 21, 2025Risk event
- Oct 27, 2025Trademark
- Jul 17, 20258-KMaterial agreement signedItem 1.01
- Jun 9, 20258-KShareholder vote resultsItem 5.07
- May 23, 20258-KMaterial agreement signedItem 1.01
- Feb 13, 202510-KAnnual report (10-K)0 risk factors added, 0 removed
- Feb 3, 2025Risk event
- Jan 14, 2025Trademark
- Jan 14, 2025Trademark
- Feb 14, 202410-KAnnual report (10-K)0 risk factors added, 0 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Labcorp LH | $14.3B | $1.2B | Jun 30, 2026 |
| Quest Diagnostics DGX | $11.6B | $1.4B | Jun 30, 2026 |
| Chemed Corporation CHE | $2.6B | $0.3B | Jun 30, 2026 |
| Cigna CI | $282B | — | Jun 30, 2026 |
| CVS Health CVS | $415B | $11.8B | Jun 30, 2026 |
| BrightSpring Health Services BTSG | $14.4B | $0.4B | Jun 30, 2026 |
| Henry Schein HSIC | $13.6B | $0.6B | Jun 27, 2026 |
| Viatris VTRS | $14.7B | $1.9B | Jun 30, 2026 |